FDA grants priority review to Roche’s Lunsumio® in relapsed or refractory follicular lymphoma

Roche announced that the FDA has accepted the BLA and granted priority review for Roche’s Lunsumio® (mosunetuzumab) (potential first-in-class CD20xCD3 T-cell engaging bispecific antibody) for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systematic therapies.  The FDA is expected to a make a decision by 29 December 2022.